ADIL Adial Pharmaceuticals Inc

-0.36  -9%
Previous Close 4.16
Open 3.65
Price To Book 5.07
Market Cap 24913746
Shares 6,556,249
Volume 4,439,183
Short Ratio
Av. Daily Volume 1,171,246

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 European trial planned 1Q 2019. US trials not planned.
Alcohol use disorder

Latest News

  1. Today's Research Reports on Trending Tickers: Adial Pharmaceuticals and Cancer Genetics
  2. Adial Pharmaceuticals News: ADIL Stock Is Skyrocketing Today
  3. Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl
  4. Adial Pharmaceuticals Announces Professor Hannu Alho, Emeritus Professor of Addiction Medicine at the University of Helsinki, Finland as Coordinating Principal Investigator for Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder
  5. Adial Pharmaceuticals, Analysts Coverage, Review and Target
  6. Healthcare Stocks Following New Market Trends: Premier Health Group (PHGRF) (PHGI), Alliqua BioMedical, Tonix Pharma, & Adial Pharma
  7. Adial Pharmaceuticals Establishes Scientific Advisory Board and Appoints Global Thought Leader in the Field of Alcohol Use Disorder
  8. Adial Pharmaceuticals Chairman Featured in Doctors Channel Video Discussing Alcohol Use Disorder
  9. Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals — New Research Emphasizes Economic Growth
  10. Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder
  11. Adial Pharmaceuticals Provides Business Update for the Third Quarter of 2018
  12. Addiction Drug Developer Adial Pharmaceuticals Receives Notice of Allowance of Canadian Patent for AD04 in Alcohol Use Disorder
  13. Adial Pharmaceuticals to Present at The MicroCap Conference on October 1st in New York City
  14. Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent